The FDA has accepted for review the New Drug Application for a 25mg oral formulation of semaglutide for chronic weight management.

Interim results from the Phase III ESSENCE trial published in The New England Journal of Medicine show once-weekly ...

Considering the bioequivalence study of Brexpiprazole Tablets 0.25mg /0.5 mg/1mg/2mg/3mg/4mg, the Subject Expert Committee ...

The risk for ocular problems linked to different formulations of semaglutide appear to vary, according to a new study, which ...